Nicotine pre-treatment reduces sensitivity to the interoceptive stimulus effects of commonly abused drugs as assessed with taste conditioning paradigms.
Analgesics, Opioid
/ pharmacology
Animals
Caffeine
/ pharmacology
Central Nervous System Depressants
/ pharmacology
Central Nervous System Stimulants
Conditioning, Operant
/ drug effects
Dose-Response Relationship, Drug
Ethanol
/ pharmacology
Female
Illicit Drugs
/ pharmacology
Lithium Chloride
/ pharmacology
Male
Morphine
/ pharmacology
Nicotine
/ pharmacology
Nicotinic Agonists
/ pharmacology
Rats
Rats, Long-Evans
Reinforcement, Psychology
Taste
/ drug effects
Cocaine
Ethanol
Interoception
Morphine
Nicotine
Sensitivity
Journal
Drug and alcohol dependence
ISSN: 1879-0046
Titre abrégé: Drug Alcohol Depend
Pays: Ireland
ID NLM: 7513587
Informations de publication
Date de publication:
01 01 2019
01 01 2019
Historique:
received:
10
05
2018
revised:
29
07
2018
accepted:
30
07
2018
pubmed:
26
11
2018
medline:
23
4
2019
entrez:
26
11
2018
Statut:
ppublish
Résumé
Drug pre-exposure attenuates sensitivity to the interoceptive stimulus properties of additional subsequently administered drugs in drug-induced conditioned taste avoidance (CTA) and conditioned place preference (CPP) paradigms. Specifically, nicotine, commonly used in conjunction with other addictive substances, attenuates acquisition of ethanol and caffeine CTAs and morphine-induced CPP. Because nicotine use is comorbid with a number of substance use disorders, we systematically examined the effects of nicotine pre-exposure on two different conditioning paradigms involving integration of the interoceptive stimulus properties of multiple commonly abused drugs, in male and female rats, designed to examine both the aversive and reinforcing properties of these drugs. Nicotine dose-dependently interfered with acquisition of CTA to passively administered morphine, ethanol, and cocaine, but not lithium chloride, demonstrating that the effects of nicotine are not simply a matter of reduced orosensory processing or an inability to learn such associations. Moreover, nicotine-treated rats required higher doses of drug in order to develop CTA and did not show increased acceptance of the taste of self-administered ethanol compared with saline-treated rats. These data demonstrate that nicotine pre-exposure attenuates sensitivity to the stimulus effects of multiple drugs in two conditioning paradigms, in a manner which is consistent with a reduced ability to integrate the interoceptive properties of abused drugs. Through reducing these stimulus properties of drugs of abuse, concomitant nicotine use may result in a need to increase either the frequency or strength of doses during drug-taking, thus likely contributing to enhanced addiction liability in smokers.
Sections du résumé
BACKGROUND
Drug pre-exposure attenuates sensitivity to the interoceptive stimulus properties of additional subsequently administered drugs in drug-induced conditioned taste avoidance (CTA) and conditioned place preference (CPP) paradigms. Specifically, nicotine, commonly used in conjunction with other addictive substances, attenuates acquisition of ethanol and caffeine CTAs and morphine-induced CPP.
METHODS
Because nicotine use is comorbid with a number of substance use disorders, we systematically examined the effects of nicotine pre-exposure on two different conditioning paradigms involving integration of the interoceptive stimulus properties of multiple commonly abused drugs, in male and female rats, designed to examine both the aversive and reinforcing properties of these drugs.
RESULTS
Nicotine dose-dependently interfered with acquisition of CTA to passively administered morphine, ethanol, and cocaine, but not lithium chloride, demonstrating that the effects of nicotine are not simply a matter of reduced orosensory processing or an inability to learn such associations. Moreover, nicotine-treated rats required higher doses of drug in order to develop CTA and did not show increased acceptance of the taste of self-administered ethanol compared with saline-treated rats.
CONCLUSIONS
These data demonstrate that nicotine pre-exposure attenuates sensitivity to the stimulus effects of multiple drugs in two conditioning paradigms, in a manner which is consistent with a reduced ability to integrate the interoceptive properties of abused drugs. Through reducing these stimulus properties of drugs of abuse, concomitant nicotine use may result in a need to increase either the frequency or strength of doses during drug-taking, thus likely contributing to enhanced addiction liability in smokers.
Identifiants
pubmed: 30472574
pii: S0376-8716(18)30796-8
doi: 10.1016/j.drugalcdep.2018.07.048
pmc: PMC6373761
mid: NIHMS1512416
pii:
doi:
Substances chimiques
Analgesics, Opioid
0
Central Nervous System Depressants
0
Central Nervous System Stimulants
0
Illicit Drugs
0
Nicotinic Agonists
0
Caffeine
3G6A5W338E
Ethanol
3K9958V90M
Nicotine
6M3C89ZY6R
Morphine
76I7G6D29C
Lithium Chloride
G4962QA067
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
341-350Subventions
Organisme : NIAAA NIH HHS
ID : R01 AA024112
Pays : United States
Informations de copyright
Copyright © 2018 Elsevier B.V. All rights reserved.
Références
Neuropharmacology. 2009;56 Suppl 1:139-48
pubmed: 18619474
Brain Struct Funct. 2010 Jun;214(5-6):435-50
pubmed: 20512364
J Pharm Sci. 1985 Apr;74(4):412-5
pubmed: 3999001
Biochim Biophys Acta. 2003 Feb 17;1619(3):283-90
pubmed: 12573488
Alcohol Clin Exp Res. 2018 Mar;42(3):589-602
pubmed: 29240979
Behav Brain Res. 2018 May 2;343:16-20
pubmed: 29407412
Behav Brain Res. 2006 May 15;169(2):320-4
pubmed: 16527365
Pharmacol Biochem Behav. 1985 Jun;22(6):945-8
pubmed: 2991950
J Ark Med Soc. 2012 Oct;109(5):90-3
pubmed: 23061240
Neuropsychopharmacology. 2015 Jun;40(7):1804-12
pubmed: 25630571
Pharmacol Biochem Behav. 1994 Feb;47(2):369-74
pubmed: 7908448
Pharmacol Biochem Behav. 1986 Jan;24(1):71-8
pubmed: 3945668
Front Psychiatry. 2013 Oct 18;4:137
pubmed: 24151471
Drug Alcohol Depend. 2004 Jul 15;75(1):55-65
pubmed: 15225889
Alcohol Clin Exp Res. 1994 Jun;18(3):555-9
pubmed: 7943654
Alcohol Clin Exp Res. 2009 Mar;33(3):522-30
pubmed: 19120065
Psychopharmacology (Berl). 1981;74(2):149-57
pubmed: 6267645
Biochem Pharmacol. 2011 Oct 15;82(8):984-95
pubmed: 21740894
Psychopharmacology (Berl). 1979 Mar 22;61(2):177-89
pubmed: 108735
Brain Res Bull. 2016 May;123:61-70
pubmed: 26494018
Eur J Pharmacol. 2009 May 1;609(1-3):88-95
pubmed: 19285975
Pharmacol Biochem Behav. 1987 Aug;27(4):671-5
pubmed: 2821557
Neuropsychopharmacology. 2016 Feb;41(3):906-15
pubmed: 26211731
J Comp Neurol. 2016 Jan 1;524(1):54-73
pubmed: 26053891
Brain Res Brain Res Rev. 1998 Dec;28(3):309-69
pubmed: 9858756
Neurosci Biobehav Rev. 1995 Spring;19(1):143-57
pubmed: 7770194
Eur Neuropsychopharmacol. 1998 May;8(2):79-87
pubmed: 9619685
Am J Drug Alcohol Abuse. 2017 Mar;43(2):155-170
pubmed: 27589579
J Psychopharmacol. 2013 Sep;27(9):837-44
pubmed: 23784741
Pharmacol Biochem Behav. 2003 Jan;74(2):363-9
pubmed: 12479956
Psychopharmacology (Berl). 2007 Feb;190(3):269-319
pubmed: 16896961
Behav Cogn Neurosci Rev. 2004 Sep;3(3):143-58
pubmed: 15653812
Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1162-7
pubmed: 24395785
Life Sci. 2006 Aug 8;79(11):1069-80
pubmed: 16600311
Pharmacol Biochem Behav. 2007 Aug-Sep;87(3):321-30
pubmed: 17561237
Pharmacol Biochem Behav. 2011 Jul;99(1):7-16
pubmed: 21420998
Pharmacol Biochem Behav. 2003 Apr;75(1):223-33
pubmed: 12759131
Behav Neurosci. 2008 Oct;122(5):1038-50
pubmed: 18823161
Learn Behav. 2003 May;31(2):165-72
pubmed: 12882375
Behav Neurosci. 2015 Aug;129(4):502-11
pubmed: 26076340
Behav Neurosci. 2000 Apr;114(2):353-63
pubmed: 10832796
Psychopharmacology (Berl). 2005 Jul;180(2):258-66
pubmed: 15682294
Pharmacol Biochem Behav. 1988 Jul;30(3):693-9
pubmed: 3211979
Neuroscience. 2017 Sep 1;358:13-27
pubmed: 28663092
Pharmacol Biochem Behav. 1999 Feb;62(2):215-21
pubmed: 9972686
Drug Alcohol Depend. 2011 Jan 15;113(2-3):222-8
pubmed: 20863629
Behav Neurosci. 2015 Aug;129(4):380-8
pubmed: 26214212
Pharmacol Biochem Behav. 2001 May-Jun;69(1-2):209-17
pubmed: 11420088
Pharmacol Biochem Behav. 2001 Dec;70(4):515-30
pubmed: 11796151
Behav Processes. 2015 Jun;115:169-80
pubmed: 25895858
Psychopharmacology (Berl). 2001 Dec;159(1):70-6
pubmed: 11797072
Pharmacol Biochem Behav. 2010 Apr;95(2):230-4
pubmed: 20122955
Med Hypotheses. 2011 Dec;77(6):1071-3
pubmed: 22001127
Psychopharmacology (Berl). 1996 Jul;126(2):132-9
pubmed: 8856832
Eur J Pharmacol. 2005 May 16;515(1-3):117-27
pubmed: 15899481
Neuropsychopharmacology. 2014 Oct;39(11):2584-93
pubmed: 24823947
Psychopharmacology (Berl). 2000 Sep;151(4):392-405
pubmed: 11026746
Behav Neurosci. 2013 Dec;127(6):899-912
pubmed: 24341714
J Opioid Manag. 2012 Jul-Aug;8(4):227-35
pubmed: 22941850
Eur J Neurosci. 2016 Oct;44(8):2569-2580
pubmed: 27543844